Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Organisation › Details

Albireo Pharma Inc. (Nasdaq: ALBO)

Albireo Pharma, Inc. (NASDAQ:ALBO), is a clinical-stage company focused on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in phase 2 of development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo's pipeline includes assets in phase 3 for chronic constipation, phase 2 for bile acid malabsorption and pre-clinical development for NASH. Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden. *


Period Start 2020-07-11 existent
  Group Ipsen (Group)
Products Industry DRUGS, ORPHAN
  Industry 2 Bylvay®
Person Person Cooper, Ron (Albireo 202007)
Region Region Boston, MA
  Country United States (USA)
  City n. a. Boston, MA
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: 
Record changed: 2023-07-10


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Ipsen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top